Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
TP53 mutation
Cancer:
Small Lymphocytic Lymphoma
Drug:
Rituxan (rituximab)
(
CD20 inhibitor
)
Direction:
Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
NCCN
Excerpt:
CLL/SLL with del(17p)/TP53 mutation: First-line therapy...Preferred regimens… HDMP + Rituximab
Secondary therapy:
methylprednisolone oral
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login